Global Intravenous (IV) Iron Drugs Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2024

  • receipt Report ID : 156677
  • calendar_today Published On: Apr, 2019
  • file_copy Pages: 124
  • list Pharmaceuticals and Healthcare

Iron infusion is a procedure in which iron is delivered to your body intravenously, meaning into a vein through a needle. This method of delivering medication or supplementation is also known as an intravenous (IV) infusion. Iron infusions are usually prescribed by doctors to treat iron deficiency anemia.

Scope of the Report:

This report focuses on the Intravenous (IV) Iron Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Iron is one of the most important mineral present inside the human body. It carries oxygen throughout the body via the blood, which is further utilized by cells and tissue to get energy for all vital biological processes. Moreover, deficiency of iron leads to severe health problems, such as anemia and also affects mental or other memory functions in youths. To overcome this problem, oral iron supplements are recommended to maintain the iron level in the body. However, in some cases, oral administrations are not capable of maintaining the iron level in the body. For these cases, IV iron therapy is used to as part of which iron is directly injected inside the body with a needle through a vein.

The worldwide market for Intravenous (IV) Iron Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.

Market Segment by Manufacturers, this report covers

Sanofi

Allergan

AMAG Pharmaceuticals

Dalichi Sankyo

Luitpold Pharmaceuticals

Pharmacosmos

Takeda Pharmaceutical

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Ferric Carboxymaltose

Iron Sucrose

Iron Dextran

Others

Market Segment by Applications, can be divided into

Nephrology

Gynecology & Obstetrics

Gastroenterology

Oncology

Cardiology

Others

There are 15 Chapters to deeply display the global Intravenous (IV) Iron Drugs market.

Chapter 1, to describe Intravenous (IV) Iron Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of Intravenous (IV) Iron Drugs, with sales, revenue, and price of Intravenous (IV) Iron Drugs, in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of Intravenous (IV) Iron Drugs, for each region, from 2013 to 2018;

Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;

Chapter 12, Intravenous (IV) Iron Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;

Chapter 13, 14 and 15, to describe Intravenous (IV) Iron Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

Table of Contents

1 Market Overview

1.1 Intravenous (IV) Iron Drugs Introduction

1.2 Market Analysis by Type

1.2.1 Ferric Carboxymaltose

1.2.2 Iron Sucrose

1.2.3 Iron Dextran

1.2.4 Others

1.3 Market Analysis by Applications

1.3.1 Nephrology

1.3.2 Gynecology & Obstetrics

1.3.3 Gastroenterology

1.3.4 Oncology

1.3.5 Cardiology

1.3.6 Others

1.4 Market Analysis by Regions

1.4.1 North America (United States, Canada and Mexico)

1.4.1.1 United States Market States and Outlook (2013-2023)

1.4.1.2 Canada Market States and Outlook (2013-2023)

1.4.1.3 Mexico Market States and Outlook (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy)

1.4.2.1 Germany Market States and Outlook (2013-2023)

1.4.2.2 France Market States and Outlook (2013-2023)

1.4.2.3 UK Market States and Outlook (2013-2023)

1.4.2.4 Russia Market States and Outlook (2013-2023)

1.4.2.5 Italy Market States and Outlook (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

1.4.3.1 China Market States and Outlook (2013-2023)

1.4.3.2 Japan Market States and Outlook (2013-2023)

1.4.3.3 Korea Market States and Outlook (2013-2023)

1.4.3.4 India Market States and Outlook (2013-2023)

1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)

1.4.4 South America, Middle East and Africa

1.4.4.1 Brazil Market States and Outlook (2013-2023)

1.4.4.2 Egypt Market States and Outlook (2013-2023)

1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)

1.4.4.4 South Africa Market States and Outlook (2013-2023)

1.4.4.5 Nigeria Market States and Outlook (2013-2023)

1.5 Market Dynamics

1.5.1 Market Opportunities

1.5.2 Market Risk

1.5.3 Market Driving Force

2 Manufacturers Profiles

2.1 Sanofi

2.1.1 Business Overview

2.1.2 Intravenous (IV) Iron Drugs Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 Sanofi Intravenous (IV) Iron Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.2 Allergan

2.2.1 Business Overview

2.2.2 Intravenous (IV) Iron Drugs Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 Allergan Intravenous (IV) Iron Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.3 AMAG Pharmaceuticals

2.3.1 Business Overview

2.3.2 Intravenous (IV) Iron Drugs Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 AMAG Pharmaceuticals Intravenous (IV) Iron Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.4 Dalichi Sankyo

2.4.1 Business Overview

2.4.2 Intravenous (IV) Iron Drugs Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 Dalichi Sankyo Intravenous (IV) Iron Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.5 Luitpold Pharmaceuticals

2.5.1 Business Overview

2.5.2 Intravenous (IV) Iron Drugs Type and Applications

2.5.2.1 Product A

2.5.2.2 Product B

2.5.3 Luitpold Pharmaceuticals Intravenous (IV) Iron Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.6 Pharmacosmos

2.6.1 Business Overview

2.6.2 Intravenous (IV) Iron Drugs Type and Applications

2.6.2.1 Product A

2.6.2.2 Product B

2.6.3 Pharmacosmos Intravenous (IV) Iron Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.7 Takeda Pharmaceutical

2.7.1 Business Overview

2.7.2 Intravenous (IV) Iron Drugs Type and Applications

2.7.2.1 Product A

2.7.2.2 Product B

2.7.3 Takeda Pharmaceutical Intravenous (IV) Iron Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

3 Global Intravenous (IV) Iron Drugs Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)

3.1 Global Intravenous (IV) Iron Drugs Sales and Market Share by Manufacturer (2016-2017)

3.2 Global Intravenous (IV) Iron Drugs Revenue and Market Share by Manufacturer (2016-2017)

3.3 Market Concentration Rate

3.3.1 Top 3 Intravenous (IV) Iron Drugs Manufacturer Market Share in 2017

3.3.2 Top 6 Intravenous (IV) Iron Drugs Manufacturer Market Share in 2017

3.4 Market Competition Trend

4 Global Intravenous (IV) Iron Drugs Market Analysis by Regions

4.1 Global Intravenous (IV) Iron Drugs Sales, Revenue and Market Share by Regions

4.1.1 Global Intravenous (IV) Iron Drugs Sales and Market Share by Regions (2013-2018)

4.1.2 Global Intravenous (IV) Iron Drugs Revenue and Market Share by Regions (2013-2018)

4.2 North America Intravenous (IV) Iron Drugs Sales and Growth Rate (2013-2018)

4.3 Europe Intravenous (IV) Iron Drugs Sales and Growth Rate (2013-2018)

4.4 Asia-Pacific Intravenous (IV) Iron Drugs Sales and Growth Rate (2013-2018)

4.5 South America Intravenous (IV) Iron Drugs Sales and Growth Rate (2013-2018)

4.6 Middle East and Africa Intravenous (IV) Iron Drugs Sales and Growth Rate (2013-2018)

5 North America Intravenous (IV) Iron Drugs by Countries

5.1 North America Intravenous (IV) Iron Drugs Sales, Revenue and Market Share by Countries

5.1.1 North America Intravenous (IV) Iron Drugs Sales and Market Share by Countries (2013-2018)

5.1.2 North America Intravenous (IV) Iron Drugs Revenue and Market Share by Countries (2013-2018)

5.2 United States Intravenous (IV) Iron Drugs Sales and Growth Rate (2013-2018)

5.3 Canada Intravenous (IV) Iron Drugs Sales and Growth Rate (2013-2018)

5.4 Mexico Intravenous (IV) Iron Drugs Sales and Growth Rate (2013-2018)

6 Europe Intravenous (IV) Iron Drugs by Countries

6.1 Europe Intravenous (IV) Iron Drugs Sales, Revenue and Market Share by Countries

6.1.1 Europe Intravenous (IV) Iron Drugs Sales and Market Share by Countries (2013-2018)

6.1.2 Europe Intravenous (IV) Iron Drugs Revenue and Market Share by Countries (2013-2018)

6.2 Germany Intravenous (IV) Iron Drugs Sales and Growth Rate (2013-2018)

6.3 UK Intravenous (IV) Iron Drugs Sales and Growth Rate (2013-2018)

6.4 France Intravenous (IV) Iron Drugs Sales and Growth Rate (2013-2018)

6.5 Russia Intravenous (IV) Iron Drugs Sales and Growth Rate (2013-2018)

6.6 Italy Intravenous (IV) Iron Drugs Sales and Growth Rate (2013-2018)

7 Asia-Pacific Intravenous (IV) Iron Drugs by Countries

7.1 Asia-Pacific Intravenous (IV) Iron Drugs Sales, Revenue and Market Share by Countries

7.1.1 Asia-Pacific Intravenous (IV) Iron Drugs Sales and Market Share by Countries (2013-2018)

7.1.2 Asia-Pacific Intravenous (IV) Iron Drugs Revenue and Market Share by Countries (2013-2018)

7.2 China Intravenous (IV) Iron Drugs Sales and Growth Rate (2013-2018)

7.3 Japan Intravenous (IV) Iron Drugs Sales and Growth Rate (2013-2018)

7.4 Korea Intravenous (IV) Iron Drugs Sales and Growth Rate (2013-2018)

7.5 India Intravenous (IV) Iron Drugs Sales and Growth Rate (2013-2018)

7.6 Southeast Asia Intravenous (IV) Iron Drugs Sales and Growth Rate (2013-2018)

8 South America Intravenous (IV) Iron Drugs by Countries

8.1 South America Intravenous (IV) Iron Drugs Sales, Revenue and Market Share by Countries

8.1.1 South America Intravenous (IV) Iron Drugs Sales and Market Share by Countries (2013-2018)

8.1.2 South America Intravenous (IV) Iron Drugs Revenue and Market Share by Countries (2013-2018)

8.2 Brazil Intravenous (IV) Iron Drugs Sales and Growth Rate (2013-2018)

8.3 Argentina Intravenous (IV) Iron Drugs Sales and Growth Rate (2013-2018)

8.4 Colombia Intravenous (IV) Iron Drugs Sales and Growth Rate (2013-2018)

9 Middle East and Africa Intravenous (IV) Iron Drugs by Countries

9.1 Middle East and Africa Intravenous (IV) Iron Drugs Sales, Revenue and Market Share by Countries

9.1.1 Middle East and Africa Intravenous (IV) Iron Drugs Sales and Market Share by Countries (2013-2018)

9.1.2 Middle East and Africa Intravenous (IV) Iron Drugs Revenue and Market Share by Countries (2013-2018)

9.2 Saudi Arabia Intravenous (IV) Iron Drugs Sales and Growth Rate (2013-2018)

9.3 UAE Intravenous (IV) Iron Drugs Sales and Growth Rate (2013-2018)

9.4 Egypt Intravenous (IV) Iron Drugs Sales and Growth Rate (2013-2018)

9.5 Nigeria Intravenous (IV) Iron Drugs Sales and Growth Rate (2013-2018)

9.6 South Africa Intravenous (IV) Iron Drugs Sales and Growth Rate (2013-2018)

10 Global Intravenous (IV) Iron Drugs Market Segment by Type

10.1 Global Intravenous (IV) Iron Drugs Sales, Revenue and Market Share by Type (2013-2018)

10.1.1 Global Intravenous (IV) Iron Drugs Sales and Market Share by Type (2013-2018)

10.1.2 Global Intravenous (IV) Iron Drugs Revenue and Market Share by Type (2013-2018)

10.2 Ferric Carboxymaltose Sales Growth and Price

10.2.1 Global Ferric Carboxymaltose Sales Growth (2013-2018)

10.2.2 Global Ferric Carboxymaltose Price (2013-2018)

10.3 Iron Sucrose Sales Growth and Price

10.3.1 Global Iron Sucrose Sales Growth (2013-2018)

10.3.2 Global Iron Sucrose Price (2013-2018)

10.4 Iron Dextran Sales Growth and Price

10.4.1 Global Iron Dextran Sales Growth (2013-2018)

10.4.2 Global Iron Dextran Price (2013-2018)

10.5 Others Sales Growth and Price

10.5.1 Global Others Sales Growth (2013-2018)

10.5.2 Global Others Price (2013-2018)

11 Global Intravenous (IV) Iron Drugs Market Segment by Application

11.1 Global Intravenous (IV) Iron Drugs Sales Market Share by Application (2013-2018)

11.2 Nephrology Sales Growth (2013-2018)

11.3 Gynecology & Obstetrics Sales Growth (2013-2018)

11.4 Gastroenterology Sales Growth (2013-2018)

11.5 Oncology Sales Growth (2013-2018)

11.6 Cardiology Sales Growth (2013-2018)

11.7 Others Sales Growth (2013-2018)

12 Intravenous (IV) Iron Drugs Market Forecast (2018-2023)

12.1 Global Intravenous (IV) Iron Drugs Sales, Revenue and Growth Rate (2018-2023)

12.2 Intravenous (IV) Iron Drugs Market Forecast by Regions (2018-2023)

12.2.1 North America Intravenous (IV) Iron Drugs Market Forecast (2018-2023)

12.2.2 Europe Intravenous (IV) Iron Drugs Market Forecast (2018-2023)

12.2.3 Asia-Pacific Intravenous (IV) Iron Drugs Market Forecast (2018-2023)

12.2.4 South America Intravenous (IV) Iron Drugs Market Forecast (2018-2023)

12.2.5 Middle East and Africa Intravenous (IV) Iron Drugs Market Forecast (2018-2023)

12.3 Intravenous (IV) Iron Drugs Market Forecast by Type (2018-2023)

12.3.1 Global Intravenous (IV) Iron Drugs Sales Forecast by Type (2018-2023)

12.3.2 Global Intravenous (IV) Iron Drugs Market Share Forecast by Type (2018-2023)

12.4 Intravenous (IV) Iron Drugs Market Forecast by Application (2018-2023)

12.4.1 Global Intravenous (IV) Iron Drugs Sales Forecast by Application (2018-2023)

12.4.2 Global Intravenous (IV) Iron Drugs Market Share Forecast by Application (2018-2023)

13 Sales Channel, Distributors, Traders and Dealers

13.1 Sales Channel

13.1.1 Direct Marketing

13.1.2 Indirect Marketing

13.1.3 Marketing Channel Future Trend

13.2 Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendix

15.1 Methodology

15.2 Data Source

List of Tables and Figures

Figure Intravenous (IV) Iron Drugs Picture

Table Product Specifications of Intravenous (IV) Iron Drugs

Figure Global Sales Market Share of Intravenous (IV) Iron Drugs by Ty

Please fill the form below, to recieve the report sample


+1

Choose License Type

Reach Us

Email us at

sales@mrinsights.biz

Or call us on

US +1-201-465-4211

IND +91-906-779-0957

Why Choose Us

ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems

Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system

Global Outreach6 Major regions and 40+ countries level analysis accomplished

Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery